/NTRB
NTRB Stock - Nutriband Inc.
Healthcare|BiotechnologyNASDAQ
$4.49-0.88%
$0.04 (-0.88%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.44
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.94
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NTRB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.45 – $4.53
TARGET (TP)$5.16
STOP LOSS$4.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.89
52W High$11.78
52W Low$3.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.14M | $2.09M | $2.08M | $1.42M | $943,702 |
| Gross Profit | $699,302 | $862,105 | $750,409 | $504,310 | $361,324 |
| Gross Margin | 32.7% | 41.3% | 36.1% | 35.5% | 38.3% |
| Operating Income | $-6,690,000 | $-4,871,926 | $-4,147,859 | $-3,929,897 | $-2,595,945 |
| Net Income | $-10,483,000 | $-5,485,314 | $-4,810,800 | $-8,422,355 | $-3,213,514 |
| Net Margin | -489.9% | -263.0% | -231.3% | -592.2% | -340.5% |
| EPS | $-0.99 | $-0.69 | $-0.57 | $-1.06 | $-0.48 |
Company Overview
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 189.5% Upside
Now
$13
Low
$13
Average
$13
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 22nd 2025 | Noble Capital Markets | Initiation | Outperform | $13 |
Earnings History & Surprises
NTRBBeat Rate
18%
Last 11 quarters
Avg Surprise
-293.3%
EPS vs Estimate
Beats / Misses
2/9
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
-50.0%
$-0.18vs$-0.12
Q2 25
+7.7%
$-0.12vs$-0.13
Q3 25
-1147.1%
$-2.12vs$-0.17
Q4 25
+85.0%
$-0.32vs$-2.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | $-1.89 | — | — | — |
Q4 2025 | Dec 10, 2025 | $-2.13 | $-0.32 | +85.0% | ✓ BEAT |
Q3 2025 | Sep 9, 2025 | $-0.17 | $-2.12 | -1147.1% | ✗ MISS |
Q2 2025 | May 30, 2025 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q2 2025 | Apr 28, 2025 | $-0.12 | $-0.18 | -50.0% | ✗ MISS |
Q4 2024 | Dec 3, 2024 | — | $-0.12 | — | — |
Q3 2024 | Sep 3, 2024 | — | $-0.12 | — | — |
Q2 2024 | May 31, 2024 | — | $-0.21 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.16 | — | — |
Q4 2023 | Dec 12, 2023 | — | $-0.22 | — | — |
Q3 2023 | Sep 11, 2023 | — | $-0.11 | — | — |
Q2 2023 | Jun 9, 2023 | — | $-0.13 | — | — |
Q2 2023 | Apr 26, 2023 | $-0.05 | $-0.21 | -320.0% | ✗ MISS |
Q4 2022 | Dec 2, 2022 | $-0.07 | $-0.14 | -100.0% | ✗ MISS |
Q3 2022 | Sep 7, 2022 | $-0.07 | $-0.12 | -71.4% | ✗ MISS |
Q2 2022 | May 31, 2022 | $-0.06 | $-0.08 | -33.3% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $-0.09 | $-0.20 | -122.2% | ✗ MISS |
Q4 2021 | Dec 14, 2021 | $-0.03 | $-0.23 | -574.9% | ✗ MISS |
Q3 2021 | Sep 3, 2021 | $-0.01 | $-0.07 | -900.0% | ✗ MISS |
Q2 2021 | Jun 14, 2021 | — | $-0.04 | — | — |
Latest News
Nutriband Signs LOI With Qvanta Group To Explore Quantum‑AI Cybersecurity Collaboration
📈 PositiveBenzinga•Dec 18, 2025, 01:10 PM•Also:
Nutriband Responds To Executive Order Designating Illicit Fentanyl As A Weapon Of Mass Destruction, Differentiates Prescription Transdermal Fentanyl And Highlights Aversa Fentanyl Development
➖ NeutralBenzinga•Dec 18, 2025, 12:07 PM•Also:
Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
📈 PositiveBenzinga•Oct 27, 2025, 11:09 AM•Also:
Nutriband Signs Agreement Brand Institute For AVERSA Fentanyl, Plans To Commercialize Abuse-Deterrent Opioid Patch
📈 PositiveBenzinga•Oct 10, 2025, 11:05 AM•Also:
Nutriband Files Provisional Patent Application To Enhance Its Aversa Transdermal Abuse Deterrent Technology
📈 PositiveBenzinga•Oct 8, 2025, 12:43 PM•Also:
Nutriband Q2 Adj. EPS $(0.18) Misses $(0.17) Estimate, Sales $622.452K Miss $705.000K Estimate
📉 NegativeBenzinga•Sep 10, 2025, 02:05 PM•Also:
Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
📈 PositiveBenzinga•Sep 10, 2025, 01:20 PM•Also:
Frequently Asked Questions about NTRB
What is NTRB's current stock price?
Nutriband Inc. (NTRB) is currently trading at $4.49 per share. The stock has moved -0.88% today.
What is the analyst price target for NTRB?
No analyst price targets are currently available for this stock.
What sector is Nutriband Inc. in?
Nutriband Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NTRB's market cap?
Nutriband Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does NTRB pay dividends?
No, Nutriband Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to NTRB for comparison